NSAA

DRUG2 trials

Sponsors

University of Sydney, Institut de Myologie, France

Conditions

Neuromuscular DiseasesProstatic Neoplasms

Phase 3

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Active, not recruitingNCT02446405

University of SydneyProstatic Neoplasms

Start: 2014-03-31End: 2027-06-30Updated: 2025-02-06

Unknown Phase

Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient Mobility in Daily Living

Institut de Myologie, FranceNeuromuscular Diseases

Start: 2023-06-29End: 2024-06-30Target: 40Updated: 2023-09-28

Related Papers

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Journal of Clinical Oncology2025-05-282 citations

Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.

Journal of Clinical Oncology2025-05-281 citations

Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).

Journal of Clinical Oncology2025-05-28

Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies

Future Oncology2024-10-15

Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).

Journal of Clinical Oncology2024-06-017 citations

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).

Journal of Clinical Oncology2024-01-294 citations

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

2023-04-01135 citations

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2022-06-0852 citations

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

International Journal of Urology2021-05-0621 citations

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology2019-07-221114 citations

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Journal of Clinical Oncology2019-06-057 citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

New England Journal of Medicine2019-06-021519 citations

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

2018-05-01182 citations

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

2017-08-08106 citations

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).

Journal of Clinical Oncology2016-05-202 citations